Clinical Trial

Fractional Exhaled Nitric Oxide as Possible Non - Invasive Biomarker to Assess Obstructive Sleep Apnea Severity

Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
Aim of work 1. Primary aim: Asses correlation between FeNO level, OSA severity 2. Secondary aim: Clarifying FeNO's role as a biomarker to assess airway inflammation, Cut off value prediction to moderate and severe OSA and its potential significance to improve clinical management strategies for OSA patients.
Protocol Amendment History 1 change
critical Trial status changed: Not Yet Recruiting → Active, Not Recruiting 2026-05-29
Trial Details
NCT Number NCT07606898
Lead Sponsor Tanta University
Conditions Obstructive Sleep Apnea (OSA)
Enrollment 200 participants
Start Date 2026-05-25
Primary Completion 2026-09 (estimated)
Study Completion 2026-10 (estimated)
Updated on ClinicalTrials.gov 2026-06-01